Cereblon (

Adaptor Proteins, Signal Transducing / genetics Humans Lenalidomide Multiple Myeloma / drug therapy Peptide Hydrolases / genetics Pharmacogenomic Testing Polymorphism, Genetic Progression-Free Survival Thalidomide / therapeutic use Ubiquitin-Protein Ligases
Myeloma genetic and other predisposing conditions prognostication

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
03 2020
Historique:
pubmed: 21 11 2019
medline: 29 4 2021
entrez: 21 11 2019
Statut: ppublish

Résumé

Cereblon (CRBN) is crucial for antiproliferative and immunomodulatory properties of immunomodulatory drugs. The objective of this study was to verify whether germline single nucleotide polymorphisms (SNPs) in the

Identifiants

DOI: 10.1080/10428194.2019.1689391 PMID: 31746254
pubmed: 31746254
doi: 10.1080/10428194.2019.1689391
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
CRBN protein, human 0
Thalidomide 4Z8R6ORS6L
Ubiquitin-Protein Ligases EC 2.3.2.27
Peptide Hydrolases EC 3.4.-
Lenalidomide F0P408N6V4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

699-706

Auteurs

Elżbieta Iskierka-Jażdżewska (E)

Department of Hematology, Copernicus Memorial Hospital, Medical University, Lodz, Poland.
ORCID: 0000-0003-2772-8870

Federico Canzian (F)

German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID: 0000-0002-4261-4583

Anna Stępień (A)

Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Lodz, Poland.

Alessandro Martino (A)

German Cancer Research Center (DKFZ), Heidelberg, Germany.

Daniele Campa (D)

Department of Biology, University of Pisa, Pisa, Italy.

Angelica Stein (A)

German Cancer Research Center (DKFZ), Heidelberg, Germany.

Małgorzata Krawczyk-Kuliś (M)

Department of Hematology and BMT, Silesian Medical University Hospital SPSKM, Katowice, Poland.

Malwina Rybicka-Ramos (M)

Department of Hematology, Specialist Hospital No. 1 in Bytom, Bytom, Poland.

Sławomira Kyrcz-Krzemień (S)

Department of Hematology and BMT, Silesian Medical University Hospital SPSKM, Katowice, Poland.

Aleksandra Butrym (A)

Department of Cancer Prevention and Therapy, Wroclaw Medical University, Wroclaw, Poland.

Grzegorz Mazur (G)

Department of Cancer Prevention and Therapy, Wroclaw Medical University, Wroclaw, Poland.

Artur Jurczyszyn (A)

Department and Clinic of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Wroclaw, Poland.

Daria Zawirska (D)

Department and Clinic of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Wroclaw, Poland.

Norbert Grząśko (N)

Department of Haematology, Jagiellonian University Medical College, Cracow, Poland.

Waldemar Tomczak (W)

Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.

Edyta Subocz (E)

Department of Hematology, Military Institute of Medicine, Warsaw, Poland.

Marzena Wątek (M)

Department of Hematology, Holycross Cancer Center, Kielce, Poland.

Marcin Pasiarski (M)

Department of Hematology, Holycross Cancer Center, Kielce, Poland.

Marcin Rymko (M)

Department of Hematology, Copernicus Hospital, Torun, Poland.

Małgorzata Całbecka (M)

Department of Hematology, Copernicus Hospital, Torun, Poland.

Agnieszka Druzd-Sitek (A)

Department of Lymphoid Malignancies, Maria Sklodowska-Curie Institute Oncology Centre, Warsaw, Poland.

Jan Walewski (J)

Department of Lymphoid Malignancies, Maria Sklodowska-Curie Institute Oncology Centre, Warsaw, Poland.

Marcin Kruszewski (M)

Department of Hematology, University Hospital, Bydgoszcz, Poland.

Małgorzata Raźny (M)

Department of Haematology, Rydygier Memorial Hospital, Cracow, Poland.

Jan Maciej Zaucha (JM)

Department of Oncological Propaedeutics, Medical University of Gdansk, Gdansk, Poland.
Gdynia Oncology Center, Gdynia, Poland.

Marek Dudziński (M)

Rzeszow Regional Hospital, Rzeszow, Poland.

Paweł Gaj (P)

Laboratory of Human Cancer Genetics, Centre of New Technologies, University of Warsaw, Warsaw, Poland.

Tadeusz Robak (T)

Department of Hematology, Copernicus Memorial Hospital, Medical University, Lodz, Poland.

Krzysztof Warzocha (K)

Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

Krzysztof Jamroziak (K)

Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › Cereblon (
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cereblon (
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Isoindoles › Phtalimides › Lénalidomide › Cereblon (
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Cereblon (
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Cereblon (
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Services de médecine préventive › Services de diagnostic › Dépistage génétique › Test pharmacogénomique › Cereblon (
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Cereblon (
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans progression › Cereblon (
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Isoindoles › Phtalimides › Thalidomide › Cereblon (
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Ligases › Ubiquitin-protein ligase complexes › Ubiquitin-protein ligases › Cereblon (